The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Analysis of Factors Associated With Outcome in Patients With Malignant Peritoneal Mesothelioma Undergoing Surgical Debulking and Intraperitoneal Chemotherapy
Abstract
Purpose: Malignant mesothelioma (MM) arising in the peritoneal cavity is a rare neoplasm characterized by peritoneal progression and for which there are limited therapeutic options. We evaluated the peritoneal progression-free and overall survival (PFS and OS, respectively) for patients with peritoneal MM after surgical resection and regional chemotherapy. Patients and Methods: Forty-nine patients (28 males, 21 females; median age, 47 years; range, 16 to 76 years) with MM underwent laparotomy, tumor resection, continuous hyperthermic peritoneal perfusion with cisplatin (median dose 250 mg/m 2), and a single postoperative intraperitoneal dwell of fluorouracil and paclitaxel (n = 35) on protocols approved by the Institutional Review Board. Standard techniques for actuarial analyses of potential prognostic variables (Kaplan-Meier method with two-tailed log-rank test and Cox proportional hazards model) were performed. Results: At a median potential follow-up of 28.3 months, median actuarial PFS is 17 months and actuarial OS is 92 months. Factors associated with improved PFS and OS by the Cox proportional hazards model were a history of previous debulking surgery, absence of deep tissue invasion, minimal residual disease after surgical resection (OS only), and age younger than 60 years (OS only). Conclusion: Surgical resection and regional chemotherapy for MM results in durable PFS and OS. Favorable outcome is associated with age, tumor biology (selection of patients with a history of previous debulking), lack of invasive tumor growth, and minimal residual disease after tumor resection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Sugarbaker, P. H. (1995) · Annals of Surgery · doi:10.1097/00000658-199501000-00004 · Cited by 1,543
Intraperitoneal Cisplatin with Systemic Thiosulfate Protection
HOWELL, S. B., PFEIFLE, C. L., WUNG, W. E., OLSHEN, R. A., LUCAS, W. E., YON, J. L., & GREEN, M. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-6-845 · Cited by 485
Antman, K. H., Shemin, R. J., RYAN, L. M., Klegar, K., Osteen, R. T., Herman, T., Lederman, G. S., & Jm, C. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.1.147 · Cited by 289
Multiple functions of p27Kip1 and its alterations in tumor cells: a review
Sgambato, A., Cittadini, A., Faraglia, B., & Weinstein, I. B. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200004)183:1<18::aid-jcp3>3.0.co;2-s · Cited by 276
The Separation of Benign and Malignant Mesothelial Proliferations
(2000) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200009000-00001 · Cited by 272
Multimodality therapy for malignant mesothelioma based on a study of natural history
Antman, K. H., Blum, R. H., Greenberger, J. S., Flowerdew, G., Skarin, A. T., & Canellos, G. P. (1980) · The American Journal of Medicine · doi:10.1016/0002-9343(80)90103-5 · Cited by 212
Yates, D. H., Corrin, B., Stidolph, P. N., & Browne, K. (1997) · Thorax · doi:10.1136/thx.52.6.507 · Cited by 210
Kannerstein, M., & Churg, J. (1977) · Human Pathology · doi:10.1016/s0046-8177(77)80067-1 · Cited by 203
Treatment of Primary Peritoneal Mesothelioma by Continuous Hyperthermic Peritoneal Perfusion (CHPP)
Park, B. J., Alexander, H. R., Libutti, S. K., Wu, P., Royalty, D., Kranda, K. C., & Bartlett, D. L. (1999) · Annals of Surgical Oncology · doi:10.1007/s10434-999-0582-6 · Cited by 156
Self-citationResults of treatment of 33 patients with peritoneal mesothelioma
Sebbag, G., Yan, H., Shmookler, B. M., Chang, D. W.-W., & Sugarbaker, P. H. (2000) · British journal of surgery · doi:10.1046/j.1365-2168.2000.01571.x · Cited by 155
Prospective Trial for the Treatment of Malignant Peritoneal Mesothelioma
Loggie, B. W., Fleming, R. A., McQuellon, R. P., Russell, G. B., Geisinger, K. R., & Levine, E. A. (2001) · The American Surgeon · doi:10.1177/000313480106701019 · Cited by 131
Fizazi, K. S., Doubre, H., Chevalier, T. L., Riviere, A., Viala, J., Daniel, C., Robert, L., Barthélemy, P., Fandi, A., & Ruffiè, P. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.123 · Cited by 129
Mantle Cell Lymphomas Lack Expression of p27kip1, a Cyclin-Dependent Kinase Inhibitor
Quintanilla‐Martinez, L., Thiéblemont, C., Fend, F., Kumar, S., Pinyol, M., Campo, E., Jaffe, E. S., & Raffeld, M. A. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65558-7 · Cited by 113
Kerrigan, S. A. J., Turnnir, R. T., Clement, P. B., Young, R. H., & Churg, A. (2002) · Cancer · doi:10.1002/cncr.10209 · Cited by 109
Lenzi, R., Rosenblum, M. G., Verschraegen, C. F., Kudelka, A. P., Kavanagh, J. J., Hicks, M. E., Lang, E., Nash, M. A., Levy, L. B., Garcia, M. E., et al. (2002) · PubMed · Cited by 103
Genetic alterations of the p53 gene are a feature of malignant mesotheliomas.
Côté, R. J., Jhanwar, S. C., Novick, S., & Pellicer, À. (1991) · PubMed · Cited by 94
EARLY PERITONEAL MESOTHELIOMA: A TREATABLE MALIGNANCY
Antman, K., Klegar, K., Pomfret, E., Osteen, R. T., Amato, D., Larson, D., & Jm, C. (1985) · The Lancet · doi:10.1016/s0140-6736(85)90526-4 · Cited by 94
Desmoplastic diffuse mesothelioma
Cantin, R., Al-Jabi, M., & McCaughey, W. (1982) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198204000-00003 · Cited by 92
Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human malignant mesothelioma
Segers, K., Singh, S. K., Ramael, M., Marck, E. V., Backhovens, H., Voecht, J. D., & Broeckhoven, C. V. (1995) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf00199393 · Cited by 28
Cited by
Yan, T. D., Deraco, M., Baratti, D., Kusamura, S., Elias, D., Glehen, O., Gilly, F. N., Levine, E. A., Shen, P., Mohamed, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9640 · Cited by 696
Nanoparticle-mediated Hyperthermia in Cancer Therapy
Chatterjee, D. K., Diagaradjane, P., & Krishnan, S. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.72 · Cited by 417
Yan, T. D., Black, D., Savady, R., & Sugarbaker, P. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1142 · Cited by 343
Recent advances in metal nanoparticles in cancer therapy
Sharma, A., Goyal, A. K., & Rath, G. (2018) · Journal of Drug Targeting · doi:10.1080/1061186x.2017.1400553 · Cited by 341
Yan, T. D., Welch, L., Black, D., & Sugarbaker, P. H. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl428 · Cited by 308
Metadata
- Authors
- Feldman, A. L., Libutti, S. K., Pingpank, J. F., Bartlett, D. L., Beresnev, T. H., Mavroukakis, S. M., Steinberg, S. M., Liewehr, D. J., Kleiner, D. E., & Alexander, H. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-12-15
- Volume
- 21
- Issue
- 24
- Pages
- 4560-4567
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2157337438
- Cited by
- 350
- References
- 24
- FWCI
- 13.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.